Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3165
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 597
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 511
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 317
Function: require_once
98%
921
2 minutes
20
Background: Technetium- (Tc)-pyrophosphate (PYP) has been widely utilized in diagnosing bone disorders and certain cardiac conditions, such as amyloidosis, allowing for accurate imaging and detection of abnormalities within heart tissue. Rhenium, being in the same group as technetium in the periodic table, shares similar chemical properties. Rhenium- (Re) possesses favorable nuclear properties for theranostic applications.
Objectives: This study focused on labeling sodium PYP with Re and its biodistribution.
Methods: Different samples with varying amounts of PYP (5 - 22 mg), SnCl.2HO (0.2 - 6.0 mg), and ascorbic acid (0.3 - 7 mg) were prepared in vials. Initially, 0.08 mg of potassium perrhenate as a carrier in 1 mL saline was added to each vial. Subsequently, 370 - 3700 MBq of ReO was added to the initial solution. The pH of the solutions was varied between 3 and 8. The compound was shaken vigorously for 30 seconds. Product incubation was performed in a secured container for 30 minutes at room temperature.
Results: Maximum labeling yield was achieved with 10 mg of PYP, 1 mg of SnCl.2HO, 0.3 mg of ascorbic acid, and 0.08 mg of potassium perrhenate as a carrier in 1 mL with 370 MBq of ReO at pH 5. This compound showed good stability, and a radiochemical purity of 98.96% ± 0.1% was obtained. The biodistribution results of the radiolabeled ligand revealed that the maximum affinity for Re-PYP was for bone after 4 hours, which was 2.24% ± 0.667% ID/g. The maximum uptake for the kidney, spleen, and liver was 1.53% ± 0.378%, 0.13% ± 0.086%, and 0.18% ± 0.12% ID/g, respectively.
Conclusions: The present study investigated the initial labeling efficiency of Re-PYP along with its biodistribution and in vitro stability. The Re-PYP conjugate, prepared under optimized conditions, demonstrated radiochemical purity and stability. The biodistribution of the compound in mice exhibited high affinity for bone, whereas the complex was eliminated through the kidneys.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297036 | PMC |
http://dx.doi.org/10.5812/ijpr-153691 | DOI Listing |